Search results
Results from the WOW.Com Content Network
Mitragynine is an indole-based alkaloid and is one of the main psychoactive constituents in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. [4] It is an opioid that is typically consumed as a part of kratom for its pain-relieving and euphoric effects.
This is an accepted version of this page This is the latest accepted revision, reviewed on 26 February 2025. Plant species, recreational drug (kratom) Mitragyna speciosa Conservation status Least Concern (IUCN 3.1) Scientific classification Kingdom: Plantae Clade: Tracheophytes Clade: Angiosperms Clade: Eudicots Clade: Asterids Order: Gentianales Family: Rubiaceae Genus: Mitragyna Species: M ...
People report using kratom for a variety of reasons, including pain relief, fatigue and to help curb drug withdrawal symptoms, according to the National Institute on Drug Abuse.
For example, in 2010, nine people died due to the combination of O-desmethyltramadol, a μ-opioid agonist and analgesic drug, and kratom, an Asiatic medicinal plant containing mitragynine, another μ-opioid agonist, in a synthetic cannabinoid product called "Krypton". [38] And in 2013, AH-7921 was detected in smoking blends in Japan. [39]
This is sponsored content. Us Weekly is not endorsing the websites or products set forth below. The use of THC in any capacity may lead to health concerns and users should consult medical ...
A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...
Laudanum was historically used to treat a variety of conditions, but its principal use was as a pain medication and cough suppressant. Until the early 20th century, laudanum was sold without a prescription and was a constituent of many patent medicines .
Multiple studies have shown that low-dose naltrexone has promise as a treatment for chronic pain, some autoimmune disorders and cancers. [8] [9] [10] As of 2014, no peer-reviewed studies supporting low-dose naltrexone for multiple sclerosis (MS) have been published. [11] [12] Clinical trials for treatment of fibromyalgia were initiated in 2021 ...